ANDREW LERMAN: Open Payments
NPI 1407173974 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$51,700 in 246 payments from 39 companies in 2025. Trend: 2023 $68,910 · 2024 $64,855 · 2025 $51,700
Speaker / faculty: $22,490Honoraria: $12,310Consulting: $7,255Food & beverage: $5,140Travel & lodging: $3,358Education: $1,148
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 30 | $19,445 |
| Amneal Pharmaceuticals LLC | 25 | $9,793 |
| ARGENX US, INC. | 14 | $6,073 |
| MDD US Operations, LLC | 19 | $5,802 |
| Neurelis, Inc. | 12 | $5,126 |
| UCB, Inc. | 17 | $2,612 |
| ABBVIE INC. | 32 | $533 |
| PFIZER INC. | 12 | $219 |
| TG Therapeutics, Inc. | 5 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $203 |
Products named: INGREZZA, CREXONT, VYVGART, Gocovri, VALTOCO, Rystiggo, Briviact, BRIUMVI.
Industry payments across FL — which companies pay providers there.
